最新ニュース Moderna (NASDAQ:MRNA) 株価情報

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？

米製薬大手モデルナ　米国市場を牽引

Moderna Inc

WIIM

BNTX

Shares of vaccine makers are trading higher after the Daily Mail reported a new coronavirus was discovered in China.

<a href="https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html">https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html</a>
&nbsp;

Biotech

Macro Economic Events

Global

Economics

General

NVAX

'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail

<a href="https://www.statnews.com/2025/02/20/acip-cdc-vaccine-meeting-postponed/" title="https://www.statnews.com/2025/02/20/acip-cdc-vaccine-meeting-postponed/">https://www.statnews.com/2025/02/20/acip-cdc-vaccine-meeting-postponed/</a>

Health Care

Politics

STAT News: 'Meeting of key CDC vaccine advisory panel, under scrutiny by RFK Jr., is postponed'

Moderna shares are trading lower. The stock may be moving on continued weakness after Barclays downgraded the stock and UBS cut its price target earlier this week.

UBS analyst Eliana Merle maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $96 to $78.

Price Target

Analyst Ratings

UBS Maintains Buy on Moderna, Lowers Price Target to $78

U.S. stocks were lower, with the Dow Jones falling around 100 points on Tuesday.
Shares of Watsco Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) rose sharply during Tuesday's session after the company reported better-than-<a href="https://www.benzinga.com/quote/WSO/earnings">expected fourth-quarter EPS and revenue.</a>
Watsco reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.16 per share. The company reported quarterly sales of $1.75 billion which beat the analyst consensus estimate of $1.66 billion.
Watsco shares jumped 8.7% to $525.81 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) shares jumped 52% to $4.50.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) gained 26.5% to $96.57 after the company issued FY25 revenue guidance above consensus estimates.</li>
<li>WeRide Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 26.1% to $39.72.</li>
<li>Allogene Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) gained 23% to $2.51.</li>
<li>Pagaya Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) surged 19.5% to $18.36.</li>
<li>Oscar Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) climbed 16.6% to $15.70.</li>
<li>Zai Lab Ltd – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 12.5% to $32.64. Zai Lab will announce fourth quarter and full year 2024 financial results and provide recent corporate updates on Feb. 27, 2025.</li>
<li>H&amp;E Equipment Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>) gained 12.4% to $98.12. H&amp;E Equipment Services received superior proposal from Herc Holdings Inc.</li>
<li>Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 12.3% to $53.80 amid positive sentiment ahead of its annual report filing deadline on Feb 25. The shares are also rising following its upbeat FY2026 revenue projection last week.</li>
<li>Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 12% to $11.79.</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained 9.7% to $25.88 amid reports suggesting Broadcom and TSMC are considering bids for portions of the company.</li>
<li>Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) gained 7.5% to $35.48.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43781270/top-2-energy-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

ALLO

HEES

INTC

OSCR

RXRX

SMCI

ZLAB

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday

On Friday,&nbsp;Moderna Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">income of $0.55 a year ago</a>.
The COVID-19 vaccine maker reported quarterly sales of $966 million, down from $2.81 billion a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43727537/moderna-struggles-with-declining-q4-covid-vaccine-sales-stock-slides" rel="noreferrer noopener">consensus of $942.8 million</a>.
Moderna has reiterated its 2025 revenue outlook of $1.5 billion to $2.5 billion versus a consensus of $2.43 billion. Moderna expects revenue of approximately $0.2 billion in the first half of the year, reflecting the seasonality&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives" rel="noreferrer noopener">of its respiratory business</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health" rel="noreferrer noopener">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a>
The two-season Phase 3 study evaluating Moderna&#8217;s trivalent vaccine against norovirus (mRNA-1403) is fully enrolled in the Northern Hemisphere. The company is preparing for second-season enrollment in the Southern Hemisphere.
The trial is currently on FDA clinical hold following a single adverse event report of a Guillain-Barré syndrome (GBS) case, which is currently under investigation.
RBC Capital writes that Moderna notes that the background rate of GBS is 1-2 per 100,000 participants per year, so it is not surprising to see one case, given they have enrolled 250,000 participants over the last couple of years.
GBS is&nbsp;a rare neurological disorder&nbsp;in which the body&#8217;s immune system attacks the peripheral nervous system.
The company does not expect an impact on the study&#8217;s efficacy readout timeline as enrollment in the Northern Hemisphere has already been completed.&nbsp;The timing of the Phase 3 readout will be dependent on case accruals.
The company&#8217;s cytomegalovirus (CMV) vaccine did not meet the criteria for early efficacy in a <a target="_blank" href="https://www.benzinga.com/25/01/43314068/moderna-stock-is-sliding-wednesday-heres-why" rel="noreferrer noopener">Phase 3 trial</a>.
Moderna still expects data (after 112 cases) this year, and RBC analyst Luca Issi writes that Moderna remains upbeat about the opportunity.
RBC Capital says it still has confidence in Moderna&#8217;s cancer vaccine and its long-term potential, but challenges like declining COVID demand and slow RSV uptake remain in the short term. RBC Capital maintains a Sector Perform rating with a <a href="https://www.benzinga.com/briefs" target="_blank" rel="noreferrer noopener">price target of $40</a>.
Barclays analyst Gena Wang downgrades Moderna from Overweight to Equal-Weight and lowers the price target from $111 to $45.
<h2 class="wp-block-heading">Moderna Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Moderna have an average 1-year price target of $53.9, representing an expected upside of 52.24%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 3 analysts have bearish recommendations on Moderna, while 2 analysts have bullish ratings. The street high price target from Goldman Sachs is $99.0, while the street low from B of A Securities is $34.0.
Price Action: MRNA stock is up 7.51% at $35.47 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43791187/costco-travel-taps-travelport-tech-to-upgrade-booking-experience" target="_blank" rel="noreferrer noopener">Costco Travel Taps Travelport Tech To Upgrade Booking Experience</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Analyst Color

Earnings

Downgrades

Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges

RBC Capital analyst Luca Issi reiterates Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Sector Perform and maintains $40 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Moderna, Maintains $40 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Craig Hettenbach downgraded the rating for Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) from Overweight to Equal-Weight and raised the price target from $42 to $60. Hims &amp; Hers Health shares closed at $60.47 on Friday. <a href="https://www.benzinga.com/quote/HIMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst James Shin downgraded the rating for Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowered the price target from $128 to $105. Merck shares closed at $83.01 on Friday. <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Alex Zukin downgraded Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from Outperform to Peer Perform. Datadog shares closed at $131.01 on Friday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Gena Wang downgraded the rating for Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Overweight to Equal-Weight and lowered the price target from $111 to $45. Moderna shares closed at $32.99 on Friday. <a href="https://www.benzinga.com/quote/MRNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Paul Fremont downgraded Portland General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) from Buy to Neutral. Portland Gen Electric shares closed at $41.64 on Friday. <a href="https://www.benzinga.com/quote/POR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MRNA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="551" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-1024x551.png" alt="" class="wp-image-786944" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-1024x551.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-768x413.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Pre-Market Outlook

DDOG

Hims & Hers Health, Inc. Class A Common Stock

HIMS

This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Barclays analyst Gena Wang downgrades Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Overweight to Equal-Weight and lowers the price target from $111 to $45.

Barclays Downgrades Moderna to Equal-Weight, Lowers Price Target to $45

Robert F. Kennedy Jr. has been sworn in as Secretart oy Health and Human Services (HHS), a move that could shake up the healthcare sector—including health insurance stocks and the ETFs that hold them. ETFs like iShares U.S. Healthcare Providers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHF#NYSE">IHF</a>) and SPDR Select Sector Fund &#8211; Health Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>), which carry <a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">major insurers</a> such as UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), could be particularly impacted by regulatory shifts under Kennedy&#8217;s tutelage.
Investors tracking the health insurance sector should watch ETFs that have exposure to UnitedHealth and Elevance Health. We will come to the reason in a while, but first, <a href="https://www.benzinga.com/etfs">here are some ETFs</a> that hold the stocks:
iShares U.S. Healthcare Providers ETF– This ETF focuses on healthcare providers and insurers, with the topmost weightings in UnitedHealth and Elevance Health. It provides targeted exposure to managed care companies, hospitals, and specialized healthcare services, making it particularly sensitive to regulatory changes affecting health insurers. 
SPDR Select Sector Fund &#8211; Health Care– A broad-based healthcare ETF that includes not only major health insurers but also pharmaceutical and biotech companies. UnitedHealth is one of its largest holdings, meaning any regulatory action against insurers could impact its performance. Additionally, the fund&#8217;s significant exposure to vaccine makers like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) adds another layer to the concerns under Kennedy's leadership.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/02/43708331/robert-f-kennedys-confirmation-cannabis-advocates-question-his-new-vow-to-follow-the-science-on-marijuanas-harms">Robert F. Kennedy&#8217;s Confirmation: Cannabis Advocates Question His New Vow To &#8216;Follow The Science&#8217; On Marijuana&#8217;s Harms</a>
<h3 class="wp-block-heading">What's At Stake For Health Insurance Stocks?</h3>
On Feb. 13, the Senate voted 52 to 48 to confirm Kennedy as the overseer of key agencies such as the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Centers for Medicare and Medicaid Services (CMS).
During his Senate hearings in January, Kennedy denounced what he called the "rapacious behavior by insurance companies." He has suggested that he would support efforts to rein in abusive industry practices, including denying care and overcharging the government. 
Two major players in the space that could be affected by potential policy shifts include UnitedHealth, who is the largest Medicare Advantage insurer in the U.S., and Elevance Health, a major Medicaid managed care provider.
Naturally, stricter policies on claim approvals and government reimbursements could create headwinds for the aforementioned funds&#8217; major holdings.
Additionally, Kennedy&#8217;s appointment comes at a time when healthcare costs are soaring, and the spread of bird flu among wild birds and poultry farms is raising pandemic concerns. He has been a longtime vaccine skeptic, a stance that could have ramifications for pharmaceutical companies producing vaccines. Notably, he has questioned the safety and efficacy of bird flu vaccines, which can be bad news for vaccine-makers like Pfizer and Moderna. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/02/43741102/etfs-benefit-from-egg-straordinary-surge-in-grocery-prices">ETFs Benefit From Egg-Straordinary Surge In Grocery Prices</a></li>
</ul>
Photo: Shutterstock

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Health Care Provides Index Fund

Health Insurance ETFs in Focus as RFK Jr Takes Over HHS

Moderna shares are trading higher after the company reported a Q4 revenue beat.

Trump Order Halts Funding For School Covid Vaccine Mandates

Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&amp;P 500 and Nasdaq trading just above the flatline Friday. Traders are digesting weaker-than-expected retail sales and the potential for peace talks<a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks"> between Russia and Ukraine.&nbsp;</a>
Retail sales in the U.S. fell 0.9% month-over-month in January, significantly worse than the anticipated 0.1% drop. However, markets are largely shrugging off the weaker-than-expected retail sales figures which were likely affected by January's cold weather and California wildfires, as well as the upward revision of December results.
Geopolitical tensions eased slightly after Ukrainian President Volodymyr Zelenskyy<a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks"> told reporters</a> at the Munich Security Conference on Friday that he is willing to participate in Trump&#8217;s peace initiative and eventual talks with Russia.
The price of Crude Oil slid another 0.52% Friday and is down 9.9% over the past month as the market reacted to President Donald Trump&#8216;s plans to impose reciprocal tariffs on trade partners and news of potential peace talks to end the war in Ukraine.
The yield on the 10-year U.S. Treasury note fell to below the 4.5% threshold on Friday, extending its pullback after January's retail sales data may have indicated some weakness in the U.S. consumer. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 0.7%. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose above the $98,000 level on a midday rally Friday and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) climbed more than 7%. 
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100 </td>
<td>19,988.34</td>
<td>0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,116.90</td>
<td>0.03%</td>
</tr>
<tr>
<td>Dow Jones </td>
<td>44,602.67</td>
<td>-0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,278.93</td>
<td>-0.14%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.3% to $609.92</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.23% at $446.24</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.27% to $537.34.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.14% to $225.82.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.14% to $226.78</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.72% to $90.36.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Friday's Stock Movers:&nbsp;</h2>
Shares of Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) and SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) tanked after NVIDIA Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) latest 13F filing revealed it had dissolved its stakes in both companies.&nbsp;
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>DraftKings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)&nbsp;</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>)&nbsp;</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;</li>
<li>JFrog, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>)&nbsp;</li>
<li>Wynn Resorts Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>)&nbsp;</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)&nbsp;</li>
<li>Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)&nbsp;</li>
<li>Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>)&nbsp;</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)&nbsp;</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>)&nbsp;</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>)&nbsp;</li>
<li>Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>)&nbsp;</li>
</ul>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Image: Shutterstock

$BTC

$XRP

COIN

SPDR Dow Jones Industrial Average ETF Trust

DKNG

DXCM

FROG

NVDA

PANW

PCOR

ROKU

SERV

SOUN

iShares Trust Barclays 20+ Year Treasury Bond Fund

UDMY

WYNN

Select Sector SPDR-Consumer Discretionary

Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.00</td>
<td>$26.6K</td>
<td>2.5K</td>
<td>4.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$95.5K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$200.00</td>
<td>$192.0K</td>
<td>55</td>
<td>286</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$153.7K</td>
<td>609</td>
<td>250</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$85.00</td>
<td>$26.1K</td>
<td>2.6K</td>
<td>216</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.00</td>
<td>$56.0K</td>
<td>1.3K</td>
<td>201</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$40.1K</td>
<td>13.3K</td>
<td>156</td>
</tr>
<tr>
<td>ARWR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$27.4K</td>
<td>385</td>
<td>110</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$77.50</td>
<td>$35.0K</td>
<td>176</td>
<td>46</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.00</td>
<td>$35.6K</td>
<td>602</td>
<td>30</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a put option sweep that happens to be bullish, expiring in 35 day(s) on March 21, 2025. This event was a transfer of 533 contract(s) at a $8.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $26.6K, with a price of $50.0 per contract. There were 2587 open contracts at this strike prior to today, and today 4649 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $95.5K, with a price of $191.0 per contract. There were 1849 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we notice a call option sweep that happens to be bearish, expiring in 308 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $200.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $192.0K, with a price of $4800.0 per contract. There were 55 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we observe a put option trade with bullish sentiment. It expires in 336 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $153.7K, with a price of $615.0 per contract. There were 609 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option trade that happens to be bullish, expiring in 154 day(s) on July 18, 2025. This event was a transfer of 39 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $670.0 per contract. There were 2690 open contracts at this strike prior to today, and today 216 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 7 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $1120.0 per contract. There were 1300 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on March 21, 2025. Parties traded 59 contract(s) at a $60.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.1K, with a price of $680.0 per contract. There were 13329 open contracts at this strike prior to today, and today 156 contract(s) were bought and sold. 
• For ARWR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>), we notice a call option sweep that happens to be bullish, expiring in 126 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $276.0 per contract. There were 385 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option trade with neutral sentiment. It expires in 7 day(s) on February 21, 2025. Parties traded 35 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1000.0 per contract. There were 176 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option sweep that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 30 contract(s) at a $100.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $1177.0 per contract. There were 602 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ARWR

EXAS

SRPT

SWTX

10 Health Care Stocks With Whale Alerts In Today's Session

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Friday.
Shares of Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell sharply in today's pre-market trading after the company issued second-quarter revenue guidance <a href="https://in.benzinga.com/25/02/43715360/applied-materials-stock-slides-after-q1-report-weak-q2-revenue-guidance">below estimates</a>.
Applied Materials reported quarterly earnings of $2.38 per share which beat the $2.29 analyst consensus estimate. Quarterly revenue came in at $7.17 billion, beating the $7.14 billion consensus estimate. The company sees second-quarter earnings of $2.30 per share, plus or minus 18 cents, versus the $2.30 estimate and revenue of $7.1 billion, plus or minus $400 million, versus the $7.21 billion estimate.
Applied Materials shares tumbled 5.1% to $174.81 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Informatica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) shares dipped 35.6% to $16.21 in pre-market trading after the company reported worse-than-expected fourth-quarter sales results and issued FY25 revenue guidance below estimates.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 22.5% to $3.20 in pre-market trading after gaining 3% on Thursday.</li>
<li>Stevanato Group S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) fell 16.1% to $16.01 in pre-market trading after declining 5% on Thursday.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) shares fell 13.2% to $25.25 in pre-market trading following downbeat quarterly earnings.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) dipped 12.3% to $13.37 in pre-market trading. Nvidia reported it dissolved share stake in Soundhound in 13F.</li>
<li>Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) fell 8.6% to $134.49 in pre-market trading following weak first-quarter guidance.</li>
<li>DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) fell 7.9% to $163.00 in pre-market trading after Berkshire Hathaway trimmed its stake in the company. The dialysis provider also issued a weak outlook for 2025 as it announced its results after the market closed on Thursday.</li>
<li>Moderna, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) fell 6.3% to $29.89 in pre-market trading following fourth-quarter results.</li>
<li>Stevanato Group S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) fell 5.6% to $18.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

AMAT

INFA

SLSR

STVN

TWLO

Applied Materials, Informatica, Clearwater Paper And Other Big Stocks Moving Lower In Friday's Pre-Market Session

On Friday,&nbsp;Moderna Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">income of $0.55 a year ago</a>.
The COVID-19 vaccine maker reported quarterly sales of $966 million, down from $2.81 billion a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/ac43724876/moderna-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-business-updat" rel="noreferrer noopener">consensus of $942.8 million</a>.
Net product sales for the fourth quarter of 2024 were $938 million, reflecting a 66% year-over-year decrease. This was primarily due to the earlier launch of the updated COVID-19 vaccine in the United States, which shifted sales <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43716942/moderna-q4-earnings-preview-covid-19-vaccine-sales-bird-flu-vaccine-candidates-on-watch" rel="noreferrer noopener">into the third quarter</a>.
Additionally, international sales were lower than in 2023, reflecting the continued phase-out of advance purchase agreements.
The company reported $923 million in Spikevax (COVID-19 vaccine) sales in the fourth quarter of 2024, which includes $244 million in U.S. sales and $679 million in international sales. Spikevax sales for the full year 2024 were $3.1 billion.
In January, Moderna was awarded a tender to supply the European Union with its mRNA COVID-19 vaccine. Under the agreement, Moderna can provide the vaccine in several <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43196950/moderna-secures-european-contract-for-covid-19-vaccine" rel="noreferrer noopener">formats&nbsp;for up to four years</a>.
For the fourth quarter, Moderna reported $15 million in mRESVIA (Respiratory syncytial virus (RSV) vaccine) sales. mRESVIA sales for the full year 2024 were $25 million.
The cost of sales for the fourth quarter of 2024 was $739 million, which included third-party royalties of $45 million, inventory write-downs of $193 million, and wind-down costs of $259 million, including a non-cash charge of $238 million related to the termination of a contract manufacturing agreement.
Guidance: Moderna has reiterated its 2025 revenue outlook of $1.5 billion to $2.5 billion versus a consensus of $2.43 billion. Moderna expects revenue of approximately $0.2 billion in the first half of the year, reflecting the seasonality <a target="_blank" href="https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives" rel="noreferrer noopener">of its respiratory business</a>.
&#8220;In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth,&#8221; said Stéphane Bancel, Chief Executive Officer of Moderna.
The company expects the cost of sales to be approximately $1.2 billion, with R&amp;D expenses anticipated to be approximately $4.1 billion.
Capital expenditures for 2025 are expected to be approximately $0.4 billion, and year-end cash and investments for 2025 are projected to be approximately $6 billion.
Price Action: At last check on Friday, MRNA stock was down 3.70% to $30.46&nbsp;during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43692928/deeres-q1-earnings-beat-forecasts-yet-sales-and-profits-slide-amid-declining-equipment-demand" target="_blank" rel="noreferrer noopener">Deere Q1 Earnings: Sales Drop, Margins Shrink, Inventory Streamlining And More</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Guidance

Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides

2025 Financial Framework
<ul>
<li>Revenue: The Company reiterates 2025 expected revenue of $1.5 to $2.5 billion. Moderna expects revenue of approximately $0.2 billion in the first half of the year, reflecting the seasonality of its respiratory business.</li>
<li>Cost of Sales: Cost of sales for 2025 is expected to be approximately $1.2 billion.</li>
<li>Research and Development Expenses: Full-year 2025 research and development expenses are anticipated to be approximately $4.1 billion.</li>
<li>Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2025 are projected to be approximately $1.1 billion.</li>
<li>Income Taxes: The Company continues to expect its full-year tax expense to be negligible.</li>
<li>Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.4 billion.</li>
<li>Cash and Investments: Year-end cash and investments for 2025 are projected to be approximately $6 billion.</li>
<li>Recent Progress and Upcoming Late-Stage Pipeline Milestones</li>
<li>The Company remains focused on a prioritized research and development portfolio, delivering up to 10 product approvals through 2027.</li>
</ul>

Moderna Reiterates 2025 Expected Revenue Of $1.5B-$2.5B, The Company Expects Revenue Of Approximately $0.2B In The First Half Of The Year, Reflecting The Seasonality Of Its Respiratory Business

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported quarterly losses of $(2.91) per share which missed the analyst consensus estimate of $(2.62) by 11.07 percent. This is a 629.09 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $966.00 million which beat the analyst consensus estimate of $942.84 million by 2.46 percent. This is a 65.64 percent decrease over sales of $2.81 billion the same period last year.

Moderna Q4 2024 GAAP EPS $(2.91) Misses $(2.62) Estimate, Sales $966.00M Beat $942.84M Estimate

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, with the index moving to the &#8220;Neutral&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jones index jumping over 300 points as investors monitored recent inflation data and updates on tariff plans.
The Producer Price Index surged 3.5% year over year in January, according to Thursday's release from the Bureau of Labor Statistics. U.S. initial jobless claims declined by 7,000 from the previous week to 213,000 during the first week of February, down from market estimates of 215,000.
Some big tech stocks provided a boost to markets on Thursday, with shares of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gaining over 3% after HPE announced the first shipment of the company&#8217;s Grace Blackwell System. AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares jumped 24% after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) also added 5.8% during the session following upbeat analyst calls on the stock as well as news over new EV taxes to finance road repairs which could impact its rivals.
All sectors on the S&amp;P 500 closed on a positive note, with materials, consumer discretionary and information technology stocks recording gains on Thursday.
The Dow Jones closed higher by around 343 points to 44,711.43 on Thursday. The S&amp;P 500 climbed 1.04% to 6,115.07, while the Nasdaq Composite jumped 1.50% at 19,945.64 during Thursday's session.
Investors are awaiting earnings results from Enbridge Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>), Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) today.
At a current reading of 46.7, the index moved to the &#8220;Neutral&#8221; zone on Thursday, versus a prior reading of 43.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Long Ideas

TSLA

Dow Jumps Over 300 Points Following Recent Inflation Data; Investor Sentiment Improves, Fear & Greed Index Moves To 'Neutral' Zone

Press Releases

Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Moderna Announces Updates on Pandemic Influenza Program

Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025

Small Cap

Opinion

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

Bird Flu Leads To Egg Shortages And Price Rise In America

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

AVAI

AVTE

CTRX

DVAX

FHTX

GEHC

HPTX

HZNP

OMGA

SANA

TARS

TDOC

ZNTL

ZSPH

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

RBC Capital

Barclays

B of A Securities

Goldman Sachs

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？
<ol>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) の株価は、同社が市場予想を下回る<a class="ticker" href="https://www.benzinga.com//node/39523397" target="_blank" rel="noopener noreferrer">第3四半期決算を発表し</a>、2024年の業績予想を引き下げたことから24.12%急落した。アナリストは、株の<a class="ticker" href="https://www.benzinga.com/quote/wba/analyst-ratings" target="_blank" rel="noopener noreferrer">株価予想を引き下げている</a>。</li>
<li>Floor &amp; Decor Holdings, Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)の株は13.41%下落し、これは5月の予定住宅販売経済指標が期待を下回ったことに対するリアクションかもしれない。</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) の株価は同社のRSVワクチン接種の効果が<a class="ticker" href="https://www.benzinga.com//node/39508239" target="_blank" rel="noopener noreferrer">50%という結果</a>から11.76%下がった。</li>
<li>Birkenstock Holding Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) の株は同社が1千4百万株までの株式オファリングを<a href="https://www.benzinga.com//node/39467369" target="_blank" rel="noopener noreferrer">株主買い戻しによって行う</a>と発表したことで10.86%下落した。</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) の株は9.70%下落した。</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) の株価は同社が同社の<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">決算予想を下方修正した</a>後、9.19%下がった。</li>
<li>JD.Com, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) の株価は、米国が中国企業への<a class="ticker" href="https://www.benzinga.com//node/39521291" target="_blank" rel="noopener noreferrer">投資を抑制する規則を発表した</a>ことで8.89%下落した。</li>
<li>Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) の株価は8.02%急落した</li>
<li>International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) の株価はSuzano SA（NYSE:SUZ）が同社の<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">買収取引</a>を進展させないと発表したことに伴い、7.98%下落した。</li>
<li>Micron Technology Inc.の（NASDAQ:MU）株は、第3四半期の決算と第4四半期の見通し<a href="https://www.benzinga.com//node/39520174" target="_blank" rel="noreferrer noopener">を発表したことを受け、先週7.62%急落</a>した。</li>
</ol>

Comments

Moderna

ニュース

最新ニュース Moderna (NASDAQ:MRNA) 株価情報

月曜日, 7 01, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル